showed in-hospital mortality rates of 13.8%, 11.5%, and 6.0% in Shanghai and 15.4%, 12.3%, and 6.2% nationwide, respectively. [6, 7] The most common cause of HF-related in-hospital death is pump failure, followed by malignant arrhythmia and sudden death. [7] The China HF Registry Study (China-HF) reported an in-hospital HF mortality rate of 5.3% between 2012 and 2014, [8] similar to the 2000 rate. There are few large-scale studies on the long-term prognosis of HF patients after discharge, and only limited data are available from single centers. A report from the Peking Union Medical College Hospital showed the 1-, 2-, and 3-year mortality rates of 187 HF patients during 2007 and 2009 were 14%, 22%, and 32%, respectively. [9] Other data from 164 HF patients treated in Zhongshan Hospital, Fudan University between 2009 and 2010 suggested that the all-cause mortality was 21% after a 2.4-year follow-up. [10] China's economy, social and natural environment, standard of living, and medical and public health conditions have undergone myriad changes in recent decades, resulting in a significant change in the spectrum of HF causes. Studies suggested that the primary etiology of HF in China has transformed from rheumatic heart disease to coronary heart disease during the last 30 years of the 20 th century. [6, 7] In general, coronary heart disease, hypertension, and rheumatic heart disease are currently the primary causes of HF in China. [11] In addition, dilated cardiomyopathy and pulmonary heart disease should not be ignored. [11] Data from the China National HF Registry (CN-HF) showed that 54.6%, 49.4%, 29.1%, 21.7%, 19.9%, and 17.6% hospitalized HF patients were accompanied by hypertension, coronary heart disease, atrial fibrillation, diabetes, dilated cardiomyopathy, and valvular heart disease, respectively. [8] These comorbidities can reflect, to a certain extent, the distribution of the current etiologies of HF in China.
diagnosis status of heart failure

Application of biomarkers
Just as the serum index reflects cardiac function with great sensitivity and specificity, brain natriuretic peptide (BNP), and N-terminal pro-B-type natriuretic peptide (NT-proBNP) are recommended for HF diagnosis, evaluation, and prognosis estimation according to the published guidelines in China and abroad. [2, 3, 12] The normal reference range of NT-proBNP of China is similar to the range seen in European and American populations. The range is also higher in women than in men and increases with aging. [13] [14] [15] [16] Although clearly recommended in accepted guidelines and by expert consensus, the clinical application of BNP and NT-proBNP with respect to HF diagnosing in China is far from satisfactory. The CN Registry Study of Hospitalized HF patients found that BNP or NT-proBNP tests were only applied in 52.1% of HF patients hospitalized in 34 enrolled tertiary and secondary hospitals in 2013. [17] New biomarkers, such as soluble ST2 and Galectin-3, are currently in clinical studies in China. [18] Echocardiography Echocardiography is widely accepted as a basic tool and an essential examination for HF diagnosis. The 2014 China HF guidelines recommend echocardiography as a routine test for HF patients. [12] The application rate of echocardiography for hospitalized HF patients increased gradually from 1980 (27.6%) to 2000 (47.5%). [7] In 2013, 75.6% of hospitalized HF patients received an echocardiography examination, [17] which is considered significantly lower than that of developed countries. The low rate suggests a need for increased awareness of the critical importance of an echocardiography examination for all HF patients in China.
current treatMent of heart failure in china
Drug therapy
Studies showed that the use rates of classical HF drugs, including diuretics, nitrates, and digitalis, are relatively stable in China, although a nationwide survey reported a decreasing trend on the application of digitalis [ Figure 2 ]. A survey involving 42 hospitals reported digitalis use rates of 51.7%, 45.5%, and 40.3% in 1980, 1990, and 2000, respectively, and 63.7%, 70.2%, and 48.6% for diuretics. [7] 33% and 72.3% of HF patients received digitalis and diuretics in 2013, as reported by the CN-HF study, [17] and were similar to data reported in the China-HF study (26.1% and 67.2%). [8] The rate of nitrate use in the last 30 years remained relatively stable and ranged from 30% to 50%. [7, 8] The application of recommended drugs shown to improve HF prognosis, such as angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs), β-blockers, and aldosterone receptor antagonists, has increased year by year in China, but there is still much room for improvement [ Figure 3 ]. For example, the rate of ACEIs/ARBs use increased from 14% in 1980 to 71.7% in 2013 and β-blockers increased from 8.5% to 67.7% during the same period. [7, 17] China's use rate of similar drugs falls short when compared to Western countries. In Sweden, for example, more than 90% of HF patients are discharged with ACEIs/ARBs and β-blockers. [19] Regional differences exist in the application of these drugs in China. For example, β-blockers were prescribed to 80%-90% HF patients hospitalized in tertiary hospitals of Beijing and Shanghai, [9, 10] while their utilization rates were <50% in the primary hospitals of remote areas of China. [20, 21] This discrepancy may explain why the China-HF study found that only 54.7% and 50.6% of HF patients were prescribed ACEIs/ARBs and β-blockers nationwide. [8] Studies also found that the current compliance rate for reaching the target dose of ACEIs/ARBs and β-blockers remains low, despite a steady increase seen the use of these recommended HF medications. The compliance rate of ACEIs in a 2008-2009 survey of tertiary hospitals in Shanghai was 85.3%. [22] Nevertheless, national data showed that the compliance rate for β-blockers' was no more than 5%, [17, 21] an indication that much work is still needed on dose titration of related medications. As of this writing, it is unknown if the target dose for Chinese patients is the same as the dose used in other developed countries.
The heart rate lowering drug, ivabradine, was recently introduced into the Chinese market. Entresto (LCZ696) has now entered the drug pipeline for HF treatment in China. Efficacy of these drugs in Chinese HF patients requires further validation in the future clinical studies and practice. Although there are no large-scale studies to verify the efficacy of traditional Chinese medicine (TCM) on HF prognosis, several clinical trials have shown promising results for the use of TCM for HF therapy. For example, Qili Qiangxin Capsules were shown to further reduce the levels of NT-proBNP standard treatment for chronic HF. [23, 24] It is interesting to note that Western medicine guidelines are influencing the therapy choices of TCM doctors treating HF patients. [25] The expert consensus which emerged in 2014 from the Chinese Association of Integrative Medicine is expected to play an important role in guiding and regulating TCM treatment on HF.
[26] The CN-HF study showed that physicians with HF preserved ejection fraction (HFpEF) as they did to HF with reduced ejection fraction, [17] although these drugs were proved useless to HFpEF patients' prognosis.
Nondrug treatment
Cardiac resynchronization therapy (CRT) has been in practice in China since 1999. The implantation amount increased year by year [ Figure 4 ] [27] [28] [29] and the proportion of CRT Defibrillator (CRT-D) reached 53% in 2012. [27, 29] However, CRT/CRT-D only accounted for 1%-2% of the total pacemaker implantations per year in China, which is much lower than the levels reported in Europe and the United States. [27, 29] The high cost associated with these devices may be a main factor that limits the application of CRT/CRT-D in China.
Heart valve disease was once the leading cause of HF in China. Today, coronary heart disease reigns as the leading cause of HF in China. Surgery is the preferred treatment of valvular disease and the annual number of valvular disease surgeries in China is between 6000 and 7000. [30] In addition, transcatheter valve replacement or repair has developed rapidly in recent years. Transcatheter aortic valve implantation (TAVI) was first implemented in Shanghai in October 2010. [31] There were 200 cases of TAVI completed at 11 medical centers in China by the end of 2014. [32] China has supported a research program for TAVI treatment using a domestic-made valve to promote the development of the new technique in the country. [32] In May 2012, the first domestic transcatheter mitral valve repair using the MitraClip technique was implemented in Shanghai, [33] an indication of the rapid progress made on invasive treatment options for HF patients with valvular diseases in China.
The exploration of cell therapy for HF in China began in 2002 [34] and has since been followed by studies using cell transplantation to treat HF and its upstream diseases. These studies confirmed the safety of cell therapy in cardiovascular disease treatment and showed efficacy toward ischemic heart disease during short-term follow-up. However, the efficacy on dilated cardiomyopathy remains elusive. Cell therapy for HF now faces both problems and opportunities in China and worldwide.
For end-stage HF, heart transplantation is still the final choice. China's first heart transplant was performed in April 1978 in Shanghai. [35] In 2013, the Chinese Organ Transplantation Network reported 231 heart transplantation cases from 17 domestic centers. [36] The average hospital stay was 24 days and the mortality rate in hospital was 10.8% (25/231) . [36] A representative center from Shanghai completed 142 heart transplants between 2000 and 2007. The transplant recipients' survival rate was 91%, 80%, and 70% at 1, 3, and 5 years postoperation. [35, 37] Another center in Beijing performed 398 heart transplants between 2004 and 2013, with a 94.7%, 91.6%, 88%, and 82.6% survival rate at 1, 3, 5, and 7 years postoperation, respectively. [36] These data demonstrate that China's heart transplantation technology has matured but is restricted by the high cost of transplantation surgery and the scarcity of organ donors.
current ManageMent status of heart failure
It has been proven that systemwide HF education and patient management can improve the prognosis for HF patients when the current guidelines for recommended drug and device therapies are implemented. [38] Certainly, HF management frequently ends when a patient is discharged from the hospital in China. Only a few small studies have been conducted on the efficacy of telephone intervention, remote monitoring, exercise rehabilitation, and self-care on HF. [39] Large-scale studies are urgently needed to explore HF management systems that could be standardized and promoted nationwide. China's Ministry of Science and Technology has launched a project for long-term HF management research which brings hope for a new chapter for HF management in China.
In conclusion, while the economic and disease burden of HF in China rise daily, there remains much room for improvement with respect to HF diagnosis, treatment, and systemic management. More attention and support must be given to domestic epidemiological and clinical studies, the rapid transformation of laboratory results to clinics, and HFpEF. Every effort should be made to provide time and financial resources to develop an efficient and practical HF management system in China to optimize clinical practice and strategies for the prevention and management of HF in China.
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